Valuation: Roche Holding AG

Market Cap 289B 350B 305B 262B 490B 33,527B 492B 3,437B 1,329B 17,039B 1,315B 1,286B 54,545B P/E 2026 *
19.6x
P/E 2027 * 17.7x
Enterprise Value 299B 363B 316B 272B 508B 34,789B 511B 3,567B 1,379B 17,680B 1,365B 1,334B 56,598B EV / Sales 2026 *
4.78x
EV / Sales 2027 * 4.47x
Free-Float
88.78%
Yield 2026 *
2.77%
Yield 2027 * 2.84%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 354B
+1.28%+2.62%+51.61%+100.19% 1,014B
+1.10%+1.45%+52.49%+67.37% 644B
+0.58%+3.54%+19.57%+73.56% 464B
-0.36%+4.54%+38.71%+38.21% 354B
+1.52%+3.46%+20.13%+25.75% 265B
+2.41%+5.70%+9.06%+13.60% 253B
+0.91%-0.70%+38.25%+45.67% 203B
+2.48%-2.43%-24.40%-58.09% 186B
+2.17%+4.20%+34.41%+99.41% 183B
Average +0.69%+1.98%+26.65%+45.07% 396.31B
Weighted average by Cap. +0.06%+2.35%+35.35%+61.57%

Financials

2026 *2027 *
Net sales 62.66B 76.01B 66.2B 56.93B 106B 7,279B 107B 746B 289B 3,700B 286B 279B 11,843B 65.47B 79.43B 69.18B 59.49B 111B 7,607B 112B 780B 302B 3,866B 298B 292B 12,375B
Net income 14.84B 18B 15.68B 13.48B 25.19B 1,724B 25.31B 177B 68.34B 876B 67.62B 66.11B 2,805B 16.44B 19.94B 17.37B 14.94B 27.9B 1,910B 28.04B 196B 75.71B 971B 74.91B 73.25B 3,107B
Net Debt 10.86B 13.17B 11.47B 9.87B 18.43B 1,262B 18.52B 129B 50.02B 641B 49.49B 48.39B 2,053B 3.99B 4.85B 4.22B 3.63B 6.78B 464B 6.81B 47.58B 18.4B 236B 18.2B 17.8B 755B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!